$BZYR
BURZYNSKI RESEARCH INSTITUTE INC

2022 Q2 Form 10-Q Financial Statement

#000155837022010716 Filed on July 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $64.38K $43.84K $84.34K
YoY Change -23.67% -12.32% -28.7%
% of Gross Profit
Research & Development $167.4K $127.0K $231.9K
YoY Change -27.85% -36.48% -31.72%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $231.7K $170.9K $316.3K
YoY Change -26.73% -31.65% -30.94%
Operating Profit -$231.7K -$316.3K
YoY Change -26.73%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $0.00
YoY Change -100.0%
Pretax Income -$231.7K -$170.9K -$316.3K
YoY Change -26.73% 13.92% -30.94%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$231.7K -$170.9K -$316.3K
YoY Change -26.73% 13.92% -30.94%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 -$1.300K $0.00
COMMON SHARES
Basic Shares Outstanding 131.4M 131.4M 131.4M
Diluted Shares Outstanding 131.4M 131.4M

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.770K $3.380K $590.00
YoY Change 708.47%
Cash & Equivalents $4.766K $3.382K $594.00
Short-Term Investments
Other Short-Term Assets $700.00 $1.280K $1.420K
YoY Change -50.7% -84.73%
Inventory
Prepaid Expenses $700.00 $1.279K
Receivables
Other Receivables
Total Short-Term Assets $5.466K $4.661K $2.010K
YoY Change 171.94% 387.55% -78.39%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $5.466K $4.661K $2.010K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $5.466K $4.661K $2.010K
YoY Change 171.94% 387.55% -78.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.93K $0.00 $30.44K
YoY Change -54.25% -100.0% -78.54%
Accrued Expenses $30.22K $3.455K $32.80K
YoY Change -7.86% -75.82% -70.9%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $44.15K $3.460K $63.24K
YoY Change -30.19% -93.08% -75.16%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $44.15K $3.460K $63.24K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $44.15K $3.455K $63.24K
YoY Change -30.19% -92.62% -75.16%
SHAREHOLDERS EQUITY
Retained Earnings -$126.1M -$125.8M
YoY Change 0.78%
Common Stock $126.0M $125.8M
YoY Change 0.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$38.68K $1.206K -$61.23K
YoY Change
Total Liabilities & Shareholders Equity $5.466K $4.661K $2.010K
YoY Change 171.94% 387.55% -78.39%

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q2
OPERATING ACTIVITIES
Net Income -$231.7K -$170.9K -$316.3K
YoY Change -26.73% 13.92% -30.94%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$39.13K -$58.10K -$84.44K
YoY Change -53.65% 28.11% 1.14%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 40.52K 55.72K 84.97K
YoY Change -52.31% 25.35% 1.98%
NET CHANGE
Cash From Operating Activities -39.13K -58.10K -84.44K
Cash From Investing Activities
Cash From Financing Activities 40.52K 55.72K 84.97K
Net Change In Cash 1.384K -2.380K 532.0
YoY Change 160.15% 164.44% -432.5%
FREE CASH FLOW
Cash From Operating Activities -$39.13K -$58.10K -$84.44K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q2 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
76-0136810
CY2022Q2 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q2 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q2 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q2 dei Entity Address Address Line1
EntityAddressAddressLine1
9432 Katy Freeway
CY2022Q2 dei Amendment Flag
AmendmentFlag
false
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2022Q2 dei City Area Code
CityAreaCode
713
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2022Q2 dei Local Phone Number
LocalPhoneNumber
335-5697
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
131448444
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
131448444
CY2022Q2 dei Security12b Title
Security12bTitle
None
CY2022Q2 dei Trading Symbol
TradingSymbol
BZYR
CY2022Q2 dei Security Exchange Name
SecurityExchangeName
NONE
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
131448444
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
64383
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
131448444
CY2022Q2 dei Document Type
DocumentType
10-Q
CY2022Q2 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q2 dei Document Period End Date
DocumentPeriodEndDate
2022-05-31
CY2022Q2 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q2 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q2 dei Entity File Number
EntityFileNumber
000-23425
CY2022Q2 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 dei Entity Registrant Name
EntityRegistrantName
BURZYNSKI RESEARCH INSTITUTE INC
CY2022Q2 dei Entity Central Index Key
EntityCentralIndexKey
0000724445
CY2022Q2 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--02-28
CY2022Q2 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q2 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q2 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
CY2022Q2 dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
CY2022Q2 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2022Q2 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77055
CY2022Q2 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
131448444
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4766
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3382
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
700
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
84337
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
231737
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
316283
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-231737
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-316283
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-231737
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-316283
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1279
CY2021Q2 bzyr Adjustments To Additional Paid In Capital Cash Contributed
AdjustmentsToAdditionalPaidInCapitalCashContributed
84967
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
1206
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5466
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4661
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
167354
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
231946
CY2022Q2 us-gaap Assets Current
AssetsCurrent
5466
CY2022Q1 us-gaap Assets Current
AssetsCurrent
4661
CY2022Q2 us-gaap Assets
Assets
5466
CY2022Q1 us-gaap Assets
Assets
4661
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
13925
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30221
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3455
CY2022Q2 us-gaap Liabilities
Liabilities
44146
CY2022Q1 us-gaap Liabilities
Liabilities
3455
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
131448444
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
131448444
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
131449
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
131449
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
125900091
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
125708240
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-126070220
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-125838483
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-38680
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-231737
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-316283
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
131448444
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
131448444
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
1206
CY2022Q2 bzyr Adjustments To Additional Paid In Capital Cash Contributed
AdjustmentsToAdditionalPaidInCapitalCashContributed
40517
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
151334
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-231737
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-38680
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-45843
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
215926
CY2022Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
167078
CY2022Q2 us-gaap Revenues
Revenues
0
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-316283
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-61233
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-231737
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-316283
CY2022Q2 bzyr Clinical Trial Expenses Paid
ClinicalTrialExpensesPaid
151334
CY2021Q2 bzyr Clinical Trial Expenses Paid
ClinicalTrialExpensesPaid
215926
CY2022Q2 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-579
CY2021Q2 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
521
CY2022Q2 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
13925
CY2021Q2 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2071
CY2022Q2 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
26766
CY2021Q2 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
18514
CY2022Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39133
CY2021Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-84435
CY2022Q2 us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
40517
CY2021Q2 us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
84967
CY2022Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
40517
CY2021Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
84967
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1384
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
532
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3382
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4766
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
594
CY2022Q2 bzyr Ownership Interest Percentage Held By Company President And Chairman Of Board
OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard
0.810
CY2022Q2 bzyr Number Of Antineoplaston Drugs That Received Fda Approval
NumberOfAntineoplastonDrugsThatReceivedFDAApproval
0
CY2022Q2 bzyr Share Based Compensation Arrangement By Share Based Payment Award Number Of Plans
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans
1
CY2022Q2 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-8376
CY2021Q2 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-3232
CY2022Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1600000
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1600000
CY2021Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022Q2 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-48665
CY2021Q2 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-66419
CY2022Q2 us-gaap Income Tax Reconciliation Deductions
IncomeTaxReconciliationDeductions
48665
CY2021Q2 us-gaap Income Tax Reconciliation Deductions
IncomeTaxReconciliationDeductions
66419
CY2022Q2 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
8376
CY2021Q2 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
3232
CY2022Q2 bzyr Percentage Of Future Taxable Income Net Operating Loss Carryforwards
PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards
0.80
CY2022Q2 bzyr Percentage On Net Operating Loss Carryforwards Limit Of Taxable Income Under Coronavirus Aid Relief And Economic Security Act
PercentageOnNetOperatingLossCarryforwardsLimitOfTaxableIncomeUnderCoronavirusAidReliefAndEconomicSecurityAct
0.80
CY2022Q2 bzyr Percentage Of Future Taxable Income Net Operating Loss Carryforwards
PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards
0.80
CY2022Q2 bzyr Net Operating Loss Carry Forward Indefinitely
NetOperatingLossCarryForwardIndefinitely
118834

Files In Submission

Name View Source Status
0001558370-22-010716-index-headers.html Edgar Link pending
0001558370-22-010716-index.html Edgar Link pending
0001558370-22-010716.txt Edgar Link pending
0001558370-22-010716-xbrl.zip Edgar Link pending
bzyr-20220531.xsd Edgar Link pending
bzyr-20220531x10q.htm Edgar Link pending
bzyr-20220531x10q_htm.xml Edgar Link completed
bzyr-20220531xex31d1.htm Edgar Link pending
bzyr-20220531xex31d2.htm Edgar Link pending
bzyr-20220531xex32d1.htm Edgar Link pending
bzyr-20220531xex32d2.htm Edgar Link pending
bzyr-20220531_cal.xml Edgar Link unprocessable
bzyr-20220531_def.xml Edgar Link unprocessable
bzyr-20220531_lab.xml Edgar Link unprocessable
bzyr-20220531_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending